champc/iStock via Getty Images Clinical-stage biotechnology company Vaxart ( NASDAQ: VXRT ) announced an underwritten offering of 50M shares at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per share.
Gross proceeds to Vaxart from the offering are expected to be $40M. The offering is expected to close on or about June 17, 2024. The stock price scaled 60% to $1.
20 during after hours of trading on Thursday. More on Vaxart Vaxart soars after hours on $453M award to evaluate COVID-19 oral pill vaccine candidate Vaxart up 10% on quarterly revenue beat, eyes COVID oral vaccine trial start in Q2 Seeking Alpha’s Quant Rating on Vaxart Historical earnings data for Vaxart.